+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

2019 Obsessive Compulsive Disorder Clinical Trials Guide- Companies, Drugs, Phases, Subjects, Current Status and Outlook to 2025

  • ID: 4768240
  • Report
  • April 2019
  • Region: Global
  • 122 pages
  • VPA Research
1 of 3

FEATURED COMPANIES

  • Allergan Plc
  • AstraZeneca Plc
  • Eli Lilly and Co
  • F. Hoffmann-La Roche Ltd
  • Johnson & Johnson
  • Mylan NV
  • MORE
The global clinical trial report- “2019 Obsessive Compulsive Disorder Clinical Trials Study” provides complete list of trials completed, ongoing and planned for Obsessive Compulsive Disorder. It presents in-depth analysis of Obsessive Compulsive Disorder clinical trials across markets and companies. The research work is for providing complete understanding into trends in Obsessive Compulsive Disorder.

The report covers a key snapshot of trial trends, enrollment trends, success trends, locations and other trends.

It also segments the Obsessive Compulsive Disorder clinical trials by:
  • Current Trial Status
  • Type of the trial
  • Sponsor Type
  • Enrollment Trends
  • Region
  • Countries
  • Trial Phase
The report also identifies the potential drug candidates under development for treatment of Obsessive Compulsive Disorder

The research work is prepared through extensive and continuous research on Obsessive Compulsive Disorder trials from over 1500 sources including company websites, conferences and presentations, scientific journals, country wise and global clinical trial registries, news, health and science departments among others.

Report Scope and Coverage:
  • All major trials from 2010 to 2019 and planned trials are included in the report scope.
  • Drug candidates currently being researched for administering Obsessive Compulsive Disorder patients are identified
  • The report includes panorama of Obsessive Compulsive Disorder clinical trials across the globe
  • Trial Phase, Current Status, Sponsor Type, Location, trial type and Enrollment details are provided
  • Companies and universities focusing on Obsessive Compulsive Disorder clinical trials are analyzed along with their trial participation (trial title, trial phase and current status)
  • Average Enrollment number, insights into enrollment trends, company wise enrollment are included
  • Both interventional and observational studies are analyzed
  • News and latest developments for the past one year are presented in the report
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • Allergan Plc
  • AstraZeneca Plc
  • Eli Lilly and Co
  • F. Hoffmann-La Roche Ltd
  • Johnson & Johnson
  • Mylan NV
  • MORE
1.1 List of Figures
1.2 List of Tables

2. Executive Summary
2.1 Obsessive Compulsive Disorder Clinical Trials Overview, 2019
2.2 Premium Insights into Clinical Trials
2.2.1 Obsessive Compulsive Disorder Clinical Trials by Region
2.2.2 Average Enrollment of Obsessive Compulsive Disorder Clinical Trials
2.2.3 Companies participating in Trials
2.2.4 Drugs under Study for Obsessive Compulsive Disorder Treatment, 2019

3. Region wise Obsessive Compulsive Disorder Clinical Trials
3.1 Asia Pacific Obsessive Compulsive Disorder Clinical Trials by Country
3.2 Europe Obsessive Compulsive Disorder Clinical Trials by Country
3.3 North America Obsessive Compulsive Disorder Clinical Trials by Country
3.4 Middle East and Africa Obsessive Compulsive Disorder Clinical Trials by Country
3.5 South and Central America Obsessive Compulsive Disorder Clinical Trials by Country

4. Obsessive Compulsive Disorder Clinical Trial Trends
4.1 Start Year wise Obsessive Compulsive Disorder Clinical Trials
4.2 Phase wise Obsessive Compulsive Disorder Clinical Trials
4.3 Trial Status wise Obsessive Compulsive Disorder Clinical Trials
4.4 Trial Type wise Obsessive Compulsive Disorder Clinical Trials

5. Obsessive Compulsive Disorder Average Enrollment Trends
5.1 Average Enrollment in Obsessive Compulsive Disorder Trials by Year
5.2 Average Enrollment in Obsessive Compulsive Disorder Trials by Phase
5.3 Average Enrollment in Obsessive Compulsive Disorder Trials by Status
5.4 Average Enrollment in Obsessive Compulsive Disorder Trials by Type of Trial

6. Companies Participating in Obsessive Compulsive Disorder Clinical Trials
6.1 Obsessive Compulsive Disorder Trials by Sponsor Type
6.2 Obsessive Compulsive Disorder Average Enrollment by Sponsor Type
6.3 Subjects Recruited by Leading Sponsors

7. Trial Snapshots- Phase, Type, Title, Location, Start Year, Completion Year, Recruitment Status, Enrollment, Participating Countries, Trial Locations, Company, Drugs and Other Details
7.1 Obsessive Compulsive Disorder Trials- Phase 1
7.2 Obsessive Compulsive Disorder Trials- Phase 2
7.3 Obsessive Compulsive Disorder Trials- Phase 3
7.4 Obsessive Compulsive Disorder Trials- Phase 4

8. Appendix
8.1 Report Guidance
8.2 Research Methodology
8.3 Abbreviations
8.4 Definitions
8.5 Sources
8.6 Publisher Expertise

List of Figures
Figure 1: Obsessive Compulsive Disorder Clinical Trials by Region, 2019
Figure 2: Country wise Clinical Trials, 2019
Figure 3: Country wise Average Enrolment, 2019
Figure 4: Asia Pacific - Country wise Obsessive Compulsive Disorder Clinical Trials and Enrolment
Figure 5: Europe - Country wise Obsessive Compulsive Disorder Clinical Trials and Enrolment
Figure 6: Middle East Africa - Country wise Obsessive Compulsive Disorder Clinical Trials and Enrolment
Figure 7: North America - Country wise Obsessive Compulsive Disorder Clinical Trials and Enrolment
Figure 8: South and Central America - Country wise Obsessive Compulsive Disorder Clinical Trials and Enrolment
Figure 9: Obsessive Compulsive Disorder Clinical Trials by Phase
Figure 10: Obsessive Compulsive Disorder Clinical Trials by Trial Status
Figure 11: Obsessive Compulsive Disorder Clinical Trials by Type
Figure 12: Obsessive Compulsive Disorder Clinical Trials by Sponsor Type
Figure 13: Obsessive Compulsive Disorder Clinical Trials by Leading Sponsors
Figure 14: Obsessive Compulsive Disorder Average Enrollment by Phase
Figure 15: Obsessive Compulsive Disorder Average Enrollment by Trial Status
Figure 16: Obsessive Compulsive Disorder Average Enrollment by Type
Figure 17: Obsessive Compulsive Disorder- Average Enrolment by Type of Sponsors
Figure 18: Obsessive Compulsive Disorder- Enrolment by Leading Sponsors
Figure 19: Research Methodology

List of Tables
Table 1: Obsessive Compulsive Disorder Clinical Trials Snapshot- 2019
Table 2: Trials by Region, 2019
Table 3: Country wise Clinical Trials and Average Enrolment by Country, 2019
Table 4: Asia Pacific - Country wise Obsessive Compulsive Disorder Clinical Trials and Enrolment
Table 5: Europe - Country wise Obsessive Compulsive Disorder Clinical Trials and Enrolment
Table 6: Middle East Africa - Country wise Obsessive Compulsive Disorder Clinical Trials and Enrolment
Table 7: North America - Country wise Obsessive Compulsive Disorder Clinical Trials and Enrolment
Table 8: South and Central America - Country wise Obsessive Compulsive Disorder Clinical Trials and Enrolment
Table 9: Clinical Trials by Phase
Table 10: Clinical Trials by Trial Status
Table 11: Clinical Trials by Type
Table 12: Clinical Trials by Sponsor Type
Table 13: Clinical Trials by Leading Sponsors
Table 14: Obsessive Compulsive Disorder Average Enrollment by Phase
Table 15: Obsessive Compulsive Disorder Average Enrollment by Trial Status
Table 16: Obsessive Compulsive Disorder Average Enrollment by Type
Table 17: Obsessive Compulsive Disorder- Average Enrolment by Type of Sponsors
Table 18: Obsessive Compulsive Disorder- Enrolment by Leading Sponsors
Note: Product cover images may vary from those shown
3 of 3
  • Allergan Plc
  • AstraZeneca Plc
  • Eli Lilly and Co
  • F. Hoffmann-La Roche Ltd
  • Johnson & Johnson
  • Mylan NV
  • Pfizer Inc
  • Syneos Health Inc
  • The Lundbeck Foundation
  • Torrent Pharmaceuticals Ltd
Note: Product cover images may vary from those shown
Adroll
adroll